NLSP Valuation

NLS Pharmaceutics AG

Add to Watchlist

Advanced Chart

2.210

+0.17(8.333%)1D

Overview
Forecast
Valuation
Earnings

NLSP Relative Valuation

NLSP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NLSP is overvalued; if below, it's undervalued.

Historical Valuation

NLS Pharmaceutics AG (NLSP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.37. The fair price of NLS Pharmaceutics AG (NLSP) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.21

Fair

-0.12

Trailing

Forward

0.00

EV/EBITDA

NLS Pharmaceutics AG. (NLSP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.28

EV/EBIT

NLS Pharmaceutics AG. (NLSP) has a current EV/EBIT of -0.28. The 5-year average EV/EBIT is -2.29. The thresholds are as follows: Strongly Undervalued below -6.03, Undervalued between -6.03 and -4.16, Fairly Valued between -0.42 and -4.16, Overvalued between -0.42 and 1.44, and Strongly Overvalued above 1.44. The current Forward EV/EBIT of -0.28 falls within the Overvalued range.

0.00

NLS Pharmaceutics AG. (NLSP) has a current PS of 0.00. The 5-year average PS is 41.78. The thresholds are as follows: Strongly Undervalued below -194.26, Undervalued between -194.26 and -76.24, Fairly Valued between 159.80 and -76.24, Overvalued between 159.80 and 277.82, and Strongly Overvalued above 277.82. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.75

P/OCF

NLS Pharmaceutics AG. (NLSP) has a current P/OCF of -0.75. The 5-year average P/OCF is -0.56. The thresholds are as follows: Strongly Undervalued below -2.01, Undervalued between -2.01 and -1.28, Fairly Valued between 0.16 and -1.28, Overvalued between 0.16 and 0.88, and Strongly Overvalued above 0.88. The current Forward P/OCF of -0.75 falls within the Historic Trend Line -Fairly Valued range.

0.13

P/FCF

NLS Pharmaceutics AG. (NLSP) has a current P/FCF of 0.13. The 5-year average P/FCF is -0.84. The thresholds are as follows: Strongly Undervalued below -4.14, Undervalued between -4.14 and -2.49, Fairly Valued between 0.82 and -2.49, Overvalued between 0.82 and 2.47, and Strongly Overvalued above 2.47. The current Forward P/FCF of 0.13 falls within the Historic Trend Line -Fairly Valued range.

NLS Pharmaceutics AG (NLSP) has a current Price-to-Book (P/B) ratio of -5.23. Compared to its 3-year average P/B ratio of -0.65 , the current P/B ratio is approximately 707.77% higher. Relative to its 5-year average P/B ratio of 4.74, the current P/B ratio is about -210.28% higher. NLS Pharmaceutics AG (NLSP) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -85.98%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -74.33% , the current FCF yield is about -100.00% lower.

-5.23

P/B

Median3y

-0.65

Median5y

4.74

-66.28

FCF Yield

Median3y

-85.98

Median5y

-74.33

Competitors Valuation Multiple

The average P/S ratio for NLSP's competitors is 0.00, providing a benchmark for relative valuation. NLS Pharmaceutics AG Corp (NLSP) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Kiora Pharmaceuticals Inc

Matinas BioPharma Holdings Inc

Loss

11.44M

APRE.O

Aprea Therapeutics Inc

Performance Decomposition

Market capitalization of NLSP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NLSP in the past 1 year is driven by Unknown.